← All indications
Cystadenocarcinoma, Serous
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Drugs by status
Phase 2 trials (2)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (38)
- Foundation Medicine
- Takeda
- Bristol-Myers Squibb
- Clovis Oncology
- AstraZeneca
- Merck
- Genentech
- Pfizer
- Novartis
- Parexel
- Syndax Pharmaceuticals
- Boehringer Ingelheim
- Tesaro
- TetraLogic Pharmaceuticals
- National Institutes of Health (NIH)
- University of Pennsylvania
- Canadian Cancer Trials Group
- Harvard University
- University of Washington
- Northwell Health
- North Eastern Germany Society of Gynaecologic Oncology
- Radiation Therapy Oncology Group
- Seoul National University
- Southwest Oncology Group
- Thomas Jefferson University
- University of Oklahoma
- University of Toronto
- Yale University
- Mayo Clinic
- University of California, Los Angeles
- +8 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (1)